Board of Directors
Chief Executive Officer and interim Chair of the Board
Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015, and as interim Chair of the Board since November 2021 following the resignation of our former Chair due to health reasons. Ms. Pelletier has been responsible for the company’s growth and evolution, and she led Evofem’s transition to the public market in January 2018 (NASDAQ: EVFM).
Ms. Pelletier has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women’s healthcare market and what women want, and she attracted new investor capital. She has also led multiple equity financing rounds which have raised over $491 million.
In her more than 25 years of experience in the pharmaceutical industry, Ms. Pelletier has launched pharmaceutical brands worldwide and expanded indications on female healthcare brands in multiple countries. Her experience includes a comprehensive range of women’s healthcare products, cardiovascular, pain management, sleep therapies and medical devices. She has had oversight and accountability for Sales, Marketing, Operations, Medical Affairs, Regulatory Affairs, Manufacturing, Customer Service, Business Development and Strategic Partnerships.
Previously, Ms. Pelletier served as Vice President, Pharmaceuticals at Women First Healthcare, where she raised $40 million in capital. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit, managed worldwide partnerships, negotiated cost saving licensing agreements, assessed country infrastructures, developed commercialization plans and hired full scale teams, including contract sales forces.
In March 2020, she joined the Board of Directors for TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer. She serves as the chair of the Governance/Nomination Committee and is a member of the Audit Committee. She is also a published author, coveted keynote speaker and moderator at key healthcare and political conferences worldwide.
She has appeared at the Harvard School of Public Health, the Davos World Economic Forum, the Clinton Global Initiative, the MAKERS Conference, Women Deliver, the University of Virginia’s Darden School of Business, the University of Oregon’s Lundquist School of Business and the University of California, San Diego.
She is a trained Climate Reality Advocate and hosted a roundtable session at the International Conference on Climate Change, held in Reykjavik, Iceland. Ms. Pelletier has been profiled by The New York Times, Inc. Magazine, Cosmopolitan, Bustle, CNN, Glamour, Marie Claire, and Vogue. She was named as a New Champion for Reproductive Health by the United Nations Foundation, awarded the Athena San Diego’s Pinnacle Award for Life Sciences, named 2019 Business Woman of the Year by the San Diego Business Journal, and named to Inc. Magazine’s 2020 Female Founders 100 List.
Gillian Greer, CBE, Ph.D.
Dr. Gillian Greer has served as a member of the Evofem Biosciences board of directors since January 2018. Dr. Greer most recently served as the Chief Executive Officer of the National Council of Women of New Zealand. From 2012 to 2017, she served as the Chief Executive Officer of Volunteer Service Abroad, a New Zealand non-profit organization that sends volunteers to work with partner organizations in the Pacific. From 2006 to 2011, Dr. Greer served as Director General of the International Planned Parenthood Federation (IPPF), the world’s largest international sexual and reproductive health non-profit organization, working in 172 countries providing advocacy, education and sexual and reproductive health services, including maternal health, HIV/AIDS, family planning and adolescent health. During this time Dr. Greer also worked closely with UN agencies and governments to advocate for investment in health and human rights and served on the Board of ICON PLC, a global distributor of IPPF reproductive health commodities.
Prior to her work with IPPF, Dr. Greer served as Executive Director of the Family Planning Association of New Zealand where she was involved in international and regional advocacy training and initiatives, including chairing the Asia Pacific Alliance which included government agencies, funders and NGOs across the Asia Pacific region. From 1996 to 1998 Dr. Greer was Assistant Vice Chancellor Equity and Human Resources, Victoria University of Wellington, New Zealand. Dr. Greer’s early career was in education at secondary and tertiary levels. Dr. Greer has also served in a governance capacity for a number of charities and a university Council, as well as advisory panels to New Zealand Ministers of Foreign Affairs and Trade. From 2012 to 2017, Dr. Greer served as a Trustee of WomanCare Global International, a U.K. charity focused on empowering, educating and enabling women and girls to make informed choices about their health. She also served as a Director of WCG Cares, a U.S. non-profit organization whose primary purpose is to directly engage in and/or fund the development and implementation of programs that promote reproductive healthcare. She chaired the Volunteer Groups Alliance, the Asia Pacific Alliance, and the Ministry of Health-NGO Forum.
Dr. Greer holds a B.A. in English from the University of Auckland and a Ph.D. in New Zealand Literature, and an Honorary Doctorate from Victoria University of Wellington (2019). Throughout her career Dr. Greer has demonstrated an ongoing commitment to health, education, sustainable development, women’s empowerment, and human rights. Dr. Greer is passionate about strengthening civil society and building high performing organizations that are effective, ethical, and accountable and can clearly demonstrate their impact. Dr. Greer was made a Member of the New Zealand Order of Merit (MNZM) for services to family planning in 2005 and she was made a Commander of the British Empire (CBE) for services to international health and women’s rights in 2011. Dr. Greer continues to be in high demand as a speaker, facilitator, chairperson, and board member.
Kim Kamdar, Ph.D.
Dr. Kamdar has served as a member of the Evofem Biosciences board of directors since January 2018. Dr. Kamdar is a Managing Partner of Domain Associates, LLC, a life sciences venture capital firm, which she joined in 2005. Dr. Kamdar is current Chair of the board of directors and CEO of Aspen Neuroscience and chair of the board of directors of Truvian Sciences. She also serves on the board of directors of Epic Sciences, Obalon Therapeutics, Omniome, ROX Medical, Sera Prognostics and Singular Genomics. Past investments include Ariosa (acquired by Roche), Corthera (acquired by Novartis), BiPar Sciences (acquire by Sanofi-Aventis) and Achaogen.
Formerly, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to joining MPM, Dr. Kamdar was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Dr. Kamdar is the author of ten papers as well as the inventor on seven patents. Dr. Kamdar received her B.A. from Northwestern University and Ph.D. in biochemistry and genetics from Emory University.
Dr. Kamdar serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and is also on the non-profit board for Access Youth Academy, an organization that is transforming the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash.
Mr. O’Brien has served as a member of the Evofem Biosciences board of directors since January 2018. He served as the Director General of Ireland’s Health Service Executive, or HSE. an organization responsible for the provision of health and personal social services for the residents of Ireland from July 2012 to May 2018. Prior to his role as Director General, Mr. O’Brien was the Chief Operating Officer of the Department of Health’s Special Delivery Unit and a member of the Department’s Management Board. Mr. O’Brien previously served as Director of Clinical Strategy and Programs in the HSE and Chief Executive Officer of the National Treatment Purchase Fund.
Mr. O’Brien served as Chief Advisor to the HSE on the implementation of the National Cancer Control Strategy, Project Director for the National Plan for Radiation Oncology and is a former Chairman of the National Cancer Registry Board. Mr. O’Brien was the founding Chief Executive Officer of the National Cancer Screening Service from 2007 to May 2011, Director of BreastCheck, CervicalCheck and an Associate and Interim Director of the National Cancer Control Programme. Prior to joining the HSE, Mr. O’Brien served as Chief Executive of the Irish Family Planning Association and as the Chief Executive of the UK Family Planning Association.
Mr. O’Brien is a Council Member and Associate Faculty Member of the Irish Management Institute, a former Member of the Healthy Ireland Council and a Chartered Director of the Institute of Directors in Ireland. Mr. O’Brien also currently serves as a director and owner of Global Leadership And Governance Solutions Limited, a private limited company organized in the Republic of Ireland. Mr. O’Brien also holds a Master of Sciences in Management Practice from Trinity College, University of Dublin. Mr. O’Brien is Adjunct Assistant Professor in Health Strategy and Management at Trinity College Dublin.
Lisa Rarick, MD, FACOG
Dr. Rarick has served as a member of the Evofem Biosciences Board of Directors since February 2020. Dr. Rarick is a board-certified obstetrician/gynecologist and regulatory affairs expert with 35 years’ experience in women’s health and 15 years’ experience leading several offices within the U.S. Food and Drug Administration (FDA).
Dr. Rarick began her career at the FDA in 1988 as a Medical Officer, responsible for the management of products indicated for a variety of reproductive health conditions, including oral, transdermal and vaginal contraceptives. She became the Director for the Division of Reproductive and Urologic Products when it was formed in 1996, and later held several management roles in the Center for Drug Evaluation and Research (CDER), including Deputy Director of the Office of Drug Evaluation II and Associate Director in the Office of the Center Director.
Her final year at the FDA was spent in the Office of Women’s Health, where she focused on HIV prevention, pregnancy prevention, pre- and post-pregnancy care and menopausal therapy. She is currently a reproductive health and regulatory affairs consultant who has helped numerous companies navigate the development of their products from early-stage development through FDA approval.
Dr. Rarick received her B.S. and M.D. from the Loma Linda University School of Medicine and completed her residency training in Obstetrics and Gynecology at Georgetown University. She has been a member of the Scientific Advisory Committee for the National Institute of Child Health and Human Development since 2004 and served on the Board of Directors for Alliance Partners 360 from June 2017 – June 2019.
Mr. Rutherford has served as a member of the Evofem Biosciences board of directors since November 2015. He recently joined the Board of Spanish Biopharma business, Hifas da Terra SA, which is a leading product innovator in the field of mycotherapy, providing applications for use in both immunotherapy and oncology. He also serves on the Board and is Audit Committee Chairman of Mitchells & Butlers Plc, the UK’s largest quoted F&B leisure group. He also serves on the Board and Audit Committee of the quoted Oil & Gas shipping logistics business, Renaissance Services SAOG, based in Muscat and Dubai. He is Chairman of Brookgate Limited, a UK property development business backed by Goldman Sachs and TPG. Mr. Rutherford serves Independently on three private Scottish based family company Boards in Healthcare, Retail and Timber.
From 2012 to 2014, Mr. Rutherford served as Chairman of European Healthcare Group Limited, before its acquisition by two US based hedge funds. From 2008 to 2011, Mr. Rutherford served as Chairman and CEO of the quoted UK fund management group, MAM Funds Plc. From 2004 to 2009, Mr. Rutherford served as Chairman of SGI Funds, a Guernsey, Cayman and Hong Kong based diversified fund management group. From 2003 to 2006 Mr. Rutherford was Chairman and oversaw the restructuring of Noble House Group Limited, a large UK leisure business which was sold in 2006. In 2002 as Chairman and CEO he led the restructuring and sale of quoted UK finance specialist Euro-Sales Plc with 18 offices across Europe.
Mr. Rutherford graduated in Accountancy and Finance from Heriot Watt University and qualified as a chartered accountant with Touche Ross in 1984. Mr. Rutherford is a Harvard Business School Alumni.
Managing Partner, Adjuvant Capital
Jenny is currently a Managing Partner at Adjuvant Capital, a life sciences investment fund dedicated to supporting companies addressing significant global health challenges affecting lower- and middle-income countries. Adjuvant’s portfolio spans across drugs, vaccines, medical devices and diagnostics for high-burden infectious disease, sexual and reproductive health. Jenny currently serves on the boards of Antiva Biosciences (US), 54gene (Nigeria) and ChromaCode (US) and as a board observer on Excision Biotherapeutics (US).
Prior to Adjuvant, Jenny was a Partner at the Bill & Melinda Gates Foundation Strategic Investment Fund where she led numerous transactions across the foundation’s focus areas in global health, agriculture, nutrition, and education. She has always been passionate about improving the health and lives of those living in low-resourced settings and spent time working in Kenya and China. In Kenya, Jenny was as a volunteer consultant for Technoserve, a non-profit business consultancy for small-holder farmers and small to medium businesses.
Jenny has worked in finance for 20 years, beginning her career as an investment banker advising corporate clients in mergers and acquisitions and debt and equity financings at Goldman Sachs’ Hong Kong, New York, and San Francisco offices. She also serves on the Investment Advisory Committee at the Reproductive Health Investors’ Alliance (US), the Advisory Board of the Harvard School of Public Health Magazine and Board of Directors at ReSurge International (US)
Jenny graduated magna cum laude from Harvard University with an AB in History of Science. She lives with her husband and two young children in San Francisco, CA